A287840 Share Price Performance
₩63,300.00
30100.00 (90.66%)
Price ₩63,300.00
Share Pricen/a
Is IntoCell (KOSDAQ:287840) Using Debt In A Risky Way?
Dec 09
IntoCell, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A287840 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
IntoCell, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -696.38
- 99.56%
- -620.51%
- 41.5%
About A287840
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
